CellWell record HH-73360
A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer
Bodeker KL; Smith BJ; Berg DJ; Chandrasekharan C; Sharif S; Fei N; Vollstedt S; Brown H; Chandler M; Lorack A; McMichael S; Wulfekuhle J; Wagner BA; Buettner GR; Allen BG; Caster JM; Dion B; Kamgar M; Buatti JM; Cullen JJ
Redox biology ยท 2024
In plain language
In 34 adults with metastatic pancreatic cancer, intravenous vitamin C at 75 g three times weekly alongside gemcitabine and nab-paclitaxel raised serum ascorbate to millimolar and median survival to 16 from 8.3 months, reported with 90 percent confidence intervals.
- Evidence
- Established
- Design
- Randomized controlled trial
Cite this record: https://thecellwell.org/studies/HH-73360
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.